Prostatype Genomics AB (publ) provided sales guidance for the year 2022. Sales in 2022 are estimated to amount to SEK 700,000.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0328 SEK | -10.87% | -9.89% | -65.47% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-65.47% | 3.01M | |
-18.58% | 8.3B | |
+47.25% | 3.78B | |
-8.58% | 2.47B | |
-38.71% | 2.46B | |
-10.06% | 2.31B | |
-5.44% | 1.95B | |
-17.79% | 1.59B | |
-40.78% | 1.21B | |
+6.69% | 1.1B |
- Stock Market
- Equities
- PROGEN Stock
- News Prostatype Genomics AB
- Prostatype Genomics AB Provides Sales Guidance for the Year 2022